The EMBO Journal (2020) 39: e104006

Introduction {#embj2019104006-sec-0001}
============

The cytoskeleton protein actin can flux between globular (G‐actin) and filamentous (F‐actin) form, and this polymerization cycle is coupled to various cellular functions. The structure of actin is subdivided into four subdomains, SD 1--4, and contains a central pocket for ATP and magnesium ion. The polymerization kinetics of actin is dictated by the intrinsic nucleotide hydrolysis kinetics, phosphate release, and ATP turnover cycle (Pollard, [1986](#embj2019104006-bib-0035){ref-type="ref"}; Kudryashov & Reisler, [2013](#embj2019104006-bib-0023){ref-type="ref"}). The presence and absence of γ‐phosphate at the nucleotide‐binding pocket induces conformational changes that leads to opening and closing of DNase‐binding loop (D‐loop), respectively (Kudryashov & Reisler, [2013](#embj2019104006-bib-0023){ref-type="ref"}; Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}; Chou & Pollard, [2019](#embj2019104006-bib-0010){ref-type="ref"}). In cells, several actin regulators can create an array of F‐actin structures along with the nucleotide turnover and kinetics (Pollard, [2016](#embj2019104006-bib-0036){ref-type="ref"}), for example, stress fibers, cortical actin, lamellipodia, and filopodia (Hall, [1998](#embj2019104006-bib-0019){ref-type="ref"}); all of them show differential actin dynamics and are linked to a specialized actin‐mediated cellular process. To better understand these processes, researchers often use fluorescent probes that label actin and visualize them using various microscopy methods (Melak *et al*, [2017](#embj2019104006-bib-0028){ref-type="ref"}). These markers broadly can be categorized into fluorescent‐tagged actin, toxins, peptides, and proteins with actin‐binding domains (ABDs).

Fluorescent protein variants tagged at the amino‐terminus of the actin gene have been used to label actin (Belin *et al*, [2014](#embj2019104006-bib-0005){ref-type="ref"}; Melak *et al*, [2017](#embj2019104006-bib-0028){ref-type="ref"}). The advantages of this approach include measurement of actin turnover in cells as well as *in vivo* whole organism studies, especially in the context of the control of expression with conditional and tissue‐specific promoters. The major disadvantage is the bulkiness of fluorescent proteins, which has been shown to impede incorporation of tagged G‐actin into growing F‐actin (Doyle & Botstein, [1996](#embj2019104006-bib-0012){ref-type="ref"}). To overcome this, fluorescent toxins that bind to F‐actin such as phalloidin (Wulf *et al*, [1979](#embj2019104006-bib-0047){ref-type="ref"}) and jasplakinolide (SiR‐actin) (Lukinavičius *et al*, [2014](#embj2019104006-bib-0027){ref-type="ref"}) have been employed, of which phalloidin is perhaps the most widely used. Both phalloidin and jasplakinolide stabilize F‐actin (Bubb *et al*, [1994](#embj2019104006-bib-0007){ref-type="ref"}), and structural investigations suggest that they both bind to same actin‐binding site. Of these toxins, the jasplakinolide‐bound F‐actin structure has been shown to mimic ADP‐Pi actin transition state, i.e., an open D‐loop conformation (Pospich *et al*, [2017](#embj2019104006-bib-0037){ref-type="ref"}; Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}). A similar conclusion for phalloidin could not be derived because the phalloidin‐bound F‐actin structures determined so far, either have myosin (Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}) or filamin (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}) bound to the filament, both of which overlap with the D‐loop region.

The other commonly used reagent for F‐actin labeling is lifeAct, a 17 amino acid peptide derived from yeast actin‐binding protein (Riedl *et al*, [2008](#embj2019104006-bib-0039){ref-type="ref"}). Since its inception, the application of lifeAct to mark actin in cells elicits polarized responses among investigators; largely because lifeAct is shown to interfere with actin dynamics (Courtemanche *et al*, [2016](#embj2019104006-bib-0011){ref-type="ref"}) and it fails to label certain actin structures in cells (Munsie *et al*, [2009](#embj2019104006-bib-0032){ref-type="ref"}; Belin *et al*, [2014](#embj2019104006-bib-0005){ref-type="ref"}; Lemieux *et al*, [2014](#embj2019104006-bib-0024){ref-type="ref"}; Spracklen *et al*, [2014](#embj2019104006-bib-0043){ref-type="ref"}). LifeAct is also known to bind both G‐actin and F‐actin, with higher affinity towards the former form of actin (Riedl *et al*, [2008](#embj2019104006-bib-0039){ref-type="ref"}). However, a detailed structural analysis of lifeAct and actin interaction is still lacking.

In addition to toxins and peptides, the alternate method of actin labeling includes calponin homology domains (CH) that binds to actin, also known as tandem ABDs. The tandem CH1 and CH2 ABDs of utrophin (UTRN‐ABD or UTRN‐261, amino acids 1--261) have been successfully employed in F‐actin visualization (Burkel *et al*, [2007](#embj2019104006-bib-0008){ref-type="ref"}). Biochemical, structural, and cell biological studies have proposed that the tandem arrangement of CH domain is important for F‐actin binding (Winder *et al*, [1995](#embj2019104006-bib-0046){ref-type="ref"}; Moores & Kendrick‐Jones, [2000](#embj2019104006-bib-0031){ref-type="ref"}; Galkin *et al*, [2002](#embj2019104006-bib-0015){ref-type="ref"}, [2003](#embj2019104006-bib-0016){ref-type="ref"}). The crystal structure and biochemical experiments carried out with peptide fragments of utrophin suggest that CH1 domain has two actin‐binding sites and the third actin‐binding site was proposed to be in CH2 domain (Levine *et al*, [1992](#embj2019104006-bib-0025){ref-type="ref"}; Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}). Although the CH domains have high similarity among them, the linker between CH domains is variable and it is unclear whether the tandem CH architecture is important for utrophin:actin interaction. This is supported by truncation studies, which show the CH1 domain has higher affinity similar to the UTRN‐ABD and the CH2 domain is important for solubility (Singh *et al*, [2014](#embj2019104006-bib-0041){ref-type="ref"}). Earlier electron microscopy studies with helical reconstruction of UTRN bound to F‐actin has attempted to address the importance of tandem CH domains but the details could not be delineated due to its low resolution of the maps (Moores & Kendrick‐Jones, [2000](#embj2019104006-bib-0031){ref-type="ref"}; Galkin *et al*, [2002](#embj2019104006-bib-0015){ref-type="ref"}). Additionally, a shorter version of utrophin, UTRN‐230 (amino acids 1--230) has been shown to specifically label Golgi actin (Belin *et al*, [2014](#embj2019104006-bib-0005){ref-type="ref"}) and nuclei actin (Du *et al*, [2015](#embj2019104006-bib-0013){ref-type="ref"}), further questioning the actin‐binding sites and requirement of the tandem CH domain for actin interaction.

It has been well documented and acknowledged in the field that no one fluorescent actin marker is superior and all of them have certain limitations (Munsie *et al*, [2009](#embj2019104006-bib-0032){ref-type="ref"}; Belin *et al*, [2014](#embj2019104006-bib-0005){ref-type="ref"}; Courtemanche *et al*, [2016](#embj2019104006-bib-0011){ref-type="ref"}). Therefore, the accepted notion is that the choice of actin markers in investigations needs to be thoroughly thought through (Lemieux *et al*, [2014](#embj2019104006-bib-0024){ref-type="ref"}; Melak *et al*, [2017](#embj2019104006-bib-0028){ref-type="ref"}). However, all the studies have been limited to cell biology investigation and there is no structural study that has compared them systematically. In order to address these structural gaps, we employed electron cryomicroscopy (cryoEM) and helical reconstruction methods to determine the structures of actin markers bound to F‐actin. Here, we describe the phalloidin‐, lifeAct‐, and utrophin‐bound F‐actin structures, representing toxin, peptide, and protein markers widely used in actin labeling and differences and similarities of their binding interface.

Results {#embj2019104006-sec-0002}
=======

Phalloidin‐bound actin mimics the actin--ADP state {#embj2019104006-sec-0003}
--------------------------------------------------

Phalloidin‐ and jasplakinolide‐bound F‐actin structures show that both share the same binding site (Bubb *et al*, [1994](#embj2019104006-bib-0007){ref-type="ref"}; Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}; Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}). Jasplakinolide binding to actin induces ADP‐Pi like actin conformation state with an open D‐loop, a nucleotide sensing region of actin (Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}). The available phalloidin structures are in complex with actomyosin or actin/filamin, where both myosin and filamin binding overlaps with the D‐loop (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}; Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}). Therefore, we determined 3.8 and 3.6 Å structures of F‐actin--ADP (called apo, as this has only ADP bound) and phalloidin bound using cryoEM and helical reconstruction, respectively (Fig [EV1](#embj2019104006-fig-0001ev){ref-type="fig"} & Table [1](#embj2019104006-tbl-0001){ref-type="table"}; [Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}). Both of these F‐actin structures contain ADP in the nucleotide‐binding site of actin and thus form the basis for the comparison of phalloidin‐induced conformational changes (Appendix Fig S1).

![F‐actin apo and phalloidin‐bound structure validation and quality control\
A--D(A, C) The overlay of the model (green) on the cryoEM map in gray and local resolution map of actin:ADP (apo) and actin:ADP‐phalloidin structures, respectively. The red density is the difference density of phalloidin in panel (C). (B, D) FSC plots of the half‐maps and the map versus model for the Actin--ADP and Actin--ADP--phalloidin, respectively. The resolutions were estimated based on 0.143 criteria for the half‐maps and 0.5 for the model versus map.](EMBJ-39-e104006-g003){#embj2019104006-fig-0001ev}

###### 

Data collection, refinement and validation statistics

  Sample/Parameters                                            F‐actin--Phalloidin          F‐actin--Apo   F‐actin--Utrophin   F‐actin--LifeAct
  ------------------------------------------------------------ ---------------------------- -------------- ------------------- ------------------
  Microscope                                                   Titan Krios G3 ‐X‐FEG, 300                                      
  Voltage                                                      300                                                             
  Defocus range (μ)                                            −1.5 to −3.0                 −1.5 to −3.0   −1.8 to −3.3        −1.8 to −3.5
  Camera                                                       Falcon III                   Falcon III     Falcon III          Falcon III
  Pixel size (Å)                                               1.38                         1.08           1.38                1.38
  Total electron dose (e/Å^2^)                                 55.67                        49.20          42.67               49.20
  Exposure time                                                1.99                         1.99           1.99                1.99
  Frames per movie                                             20                           30             20                  30
  Number of images                                             1,124                        529            765                 929
  3‐D refinement statistics and helical symmetry                                                                               
  Total number of helical segments extracted                   349,839                      111,074        259,938             297,584
  Number of segments in map                                    91,245                       64,194         149,660             74,000
  Resolution (Å)                                               3.6                          3.8            3.6                 4.2
  Helical twist                                                −167.02                      −166.8         −167.34             −166.9
  Rise                                                         27.89                        27.25          28.02               27.44
  Map sharpening factor (Å^2^)                                 −167.2                       −179.7         −177.3              −263
  Model composition and validation                                                                                             
  Non‐hydrogen atoms                                           14,722                       14,421         17,394              14,733
  Protein residues                                             1,843                        1,826          2,204               1,889
  Ligands                                                      5Mg, 5ADP, 3 Phalloidin      5Mg, 5ADP      5Mg, 5ADP           5Mg, 5ADP
  RMSD                                                                                                                         
  Bond lengths(Å)                                              0.012                        0.008          0.006               0.009
  Bond angles (°)                                              0.969                        0.929          0.767               0.916
  B‐factor (Å^2^)                                                                                                              
  Protein                                                      58.50                        51.76          68.95               79.6
  Actin                                                        58.2                         51.5           56.1                78.2
  Toxin/protein[a](#embj2019104006-note-0001){ref-type="fn"}   51.6                         --             132.6               110.3
  Ligand (ADP)                                                 52.12                        47.01          60.48               84.64
  MolProbity Score                                             2.99                         2.83           2.29                3.33
  Clashscore                                                   10.87                        7.76           5.4                 20.84
  Ramachandran plot:‐Favored                                   89.98                        91.00          95.38               88.10
  Allowed                                                      9.79                         8.89           4.52                11.90
  Outlier                                                      0.2                          0.1            0.0                 0.0
  PDB ID                                                       7BTI                         7BT7           6M5G                7BTE
  EMDB Code                                                    30179                        30171          30085               300177

Denotes Phalloidin, Utrophin, and LifeAct in the respective column.

John Wiley & Sons, Ltd

The cyclic heptapeptide, phalloidin adopts a wedge like conformation, and the binding pocket is buried in between three actin monomers (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}A & [Appendix Fig S1](#embj2019104006-sup-0001){ref-type="supplementary-material"}). Residues from the *n* + 2^nd^ actin monomer were earlier reported to involve in hydrophobic contacts with phalloidin (Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}). However, a closer inspection of the binding site reveals that the nearest residue I287 and R290 from the third actin monomer (*n* + 2^nd^ monomer) is approximately 5 Å away from phalloidin (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}B and C [Appendix Fig S1E](#embj2019104006-sup-0001){ref-type="supplementary-material"}). This indicates that phalloidin mainly interacts with two actin monomers and stabilizes the filament interface (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}A and B). The binding pocket contains a mixture of hydrophobic and charged residues contributing to the phalloidin binding (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}B and C). Phalloidin mainly interacts with E72, H73, I75, T77, L110, N111, P112, R177, D179 of *n* + 1^st^ actin monomer and T194, G197, Y198, S199, F200, E205, and L242 of *n* ^th^ actin monomer (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}B and C [Appendix Fig S1E](#embj2019104006-sup-0001){ref-type="supplementary-material"}). Superimposition of residues within the vicinity of phalloidin also does not show any major side‐chain deviations between apo and phalloidin‐bound structures (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}C).

![Phalloidin‐bound F‐actin structure resembles ADP‐actin state\
ASurface representation of F‐actin--ADP model, five monomers marked as *n* series from barbed to pointed end. A phalloidin molecule (yellow stick representation) bound between three actin monomers is highlighted.BExpanded view of phalloidin‐binding pocket as marked with red box in panel (A). The density of phalloidin from EM map is shown around the ligand.CComparison of phalloidin‐binding pocket residues between apo (in gray) and phalloidin bound (actin monomer colors as indicated in panel A) Key residues with their side chains and phalloidin are represented in stick representation.DOverlay of F‐actin--ADP (gray), ADP/Phalloidin (blue), and ADP/Jasplakinolide (orange) shows the D‐loop conformations across different structures as indicated.](EMBJ-39-e104006-g002){#embj2019104006-fig-0001}

When the apo‐, phalloidin‐, and jasplakinolide‐bound F‐actin--ADP structures were compared, no significant structural deviation was observed except in the D‐loop region (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}D). In the ADP (apo) and ADP/phalloidin actin structures, the D‐loop region remains in the closed state (rmsd 1.1 Å). While in the ADP/jasplakinolide‐bound F‐actin structure, D‐loop adopts an open conformation (Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}) (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}D), the rmsd of D‐loop between jasplakinolide versus phalloidin is 2.4 Å. Since, we have determined the undecorated F‐actin structure, we conclude that phalloidin binding does not induce any large conformational changes in actin and resembles the respective nucleotide state of F‐actin (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}D).

LifeAct and F‐actin interaction is mediated by hydrophobic contacts {#embj2019104006-sec-0004}
-------------------------------------------------------------------

From the time of its discovery, lifeAct has been widely used to detect actin using microscopy in cell biology studies (Melak *et al*, [2017](#embj2019104006-bib-0028){ref-type="ref"}). LifeAct is also known to influence actin dynamics and can bind both monomeric (G‐actin) and F‐actin (Riedl *et al*, [2008](#embj2019104006-bib-0039){ref-type="ref"}) but it is unclear how this occurs at molecular level. To gain structural insights into the lifeAct:actin complex, we determined a 4.2 Å structure of lifeAct‐bound F‐actin ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}; Fig [EV2](#embj2019104006-fig-0002ev){ref-type="fig"} & Table [1](#embj2019104006-tbl-0001){ref-type="table"}). Similar to other actin markers, binding of lifeAct to F‐actin does not alter the helical symmetry of the filament (Table [1](#embj2019104006-tbl-0001){ref-type="table"}).

![F‐actin:lifeAct complex maps, structure validation and quality control\
AOverlay of model with map, actin, and lifeAct are colored as green and red, respectively.BLocal resolution of lifeAct‐bound F‐actin map with color gradient chart determined with Resmap.CFSC plots of the half‐maps (0.143) and the map versus model (0.5) for F‐actin:lifeAct structure.DCloser view of lifeAct:F‐actin interaction with map, key residues marked.](EMBJ-39-e104006-g005){#embj2019104006-fig-0002ev}

LifeAct adopts a helical structure and binds stoichiometrically at the SD1 region of actin monomers and the carboxy‐terminus of lifeAct extends toward the D‐loop of the *n*‐2^nd^ neighboring (barbed end) actin monomer (Fig [2](#embj2019104006-fig-0002){ref-type="fig"}A and B). The helical nature of lifeAct allows one to orient its hydrophobic residues, V3, L6, I7, F10, and I13 toward the actin (Fig [2](#embj2019104006-fig-0002){ref-type="fig"}B). Complementing this hydrophobicity are cluster of hydrophobic residues Y143, I345, L346, L349 and M355 mediates lifeAct binding (Figs [2](#embj2019104006-fig-0002){ref-type="fig"}B and [EV2](#embj2019104006-fig-0002ev){ref-type="fig"}D). An interesting feature is that the lifeAct‐binding pocket involves D‐loop residues V45, M44, and M47 of the *n*‐2^nd^ actin neighbor (Figs [2](#embj2019104006-fig-0002){ref-type="fig"}B and [EV2](#embj2019104006-fig-0002ev){ref-type="fig"}D). Together these residues form a hydrophobic pocket that can accommodate the phenyl sidechain group of the F10 lifeAct peptide (Figs [2](#embj2019104006-fig-0002){ref-type="fig"}B and [EV2](#embj2019104006-fig-0002ev){ref-type="fig"}D).

![Interaction of lifeAct with F‐actin and mutational analysis\
ASurface representation of F‐actin bound to lifeAct as indicated.BCartoon representation of lifeAct (red) in expanded view with *n* and *n* + 2^nd^ actin monomers (surface representation in magenta and blue), key interacting residues are highlighted.CConfocal images of U2OS cells transiently expressing lifeAct‐GFP wild‐type and mutants of lifeAct residues interacting with F‐actin, cells were additionally stained with SiR‐actin to confirm the actin filaments. The line scan as indicated with yellow line on the cells shows the extent of lifeAct (green) and SiR‐actin (magenta) co‐staining of actin structures. Scale bar = 5 μm.DBinding affinities calculated from titration data of co‐sedimentation assays of lifeAct‐14 (1.2 μM) and lifeAct‐17 (2.2 μM) as indicated. Data points for each concentration were averaged from three independent experiments; error bars represent SD between independent experiments.\
Source data are available online for this figure.](EMBJ-39-e104006-g004){#embj2019104006-fig-0002}

To understand the importance of the hydrophobic interface, we performed mutagenesis experiment with lifeAct‐GFP. The wild‐type and mutant lifeAct were expressed in U2OS cells, and their localization was imaged with actin structures ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}). We chose V3, L6, F10, and I13 in lifeAct and replaced them with aspartic acid (Fig [2](#embj2019104006-fig-0002){ref-type="fig"}B and C). Co‐localization with the SiR‐actin probe showed that only residues that mediate hydrophobic contacts with F‐actin as described above drastically reduced binding to F‐actin in cells (Fig [2](#embj2019104006-fig-0002){ref-type="fig"}C and [Appendix Fig S2](#embj2019104006-sup-0001){ref-type="supplementary-material"}), thus validating our structural observations of lifeAct and F‐actin interaction. In addition, we generated a carboxy‐terminal truncated version of lifeAct, called lifeAct‐14 (MGVADLIKKFESIS). The lifeAct‐14 labels F‐actin to similar to the full‐length lifeAct (lifeAct‐17). Co‐sedimentation assay of lifeAct‐14 with F‐actin also shows binding constants in similar range as the lifeAct‐17 (Fig [2](#embj2019104006-fig-0002){ref-type="fig"}D). Thus, our lifeAct:F‐actin complex structure provides a platform to generate newer and better lifeAct variants with desired properties.

LifeAct senses the closed D‐loop conformation {#embj2019104006-sec-0005}
---------------------------------------------

Since lifeAct peptide binding overlaps with the D‐loop of the *n*‐2^nd^ actin neighbor, we next probed the importance of D‐loop conformation toward lifeAct and F‐actin interaction. Comparison of open (jasplakinolide‐bound F‐actin:ADP PDB: 5OOC) versus closed D‐loop states (F‐actin:ADP:lifeAct; Fig [3](#embj2019104006-fig-0003){ref-type="fig"}A) suggests that the open D‐loop state is incompatible for lifeAct binding (Fig [3](#embj2019104006-fig-0003){ref-type="fig"}B). Therefore, from the structural model of lifeAct:actin complex we reasoned that lifeAct may have preference towards different biochemical states of actin. We therefore prepared two batches of F‐actin, one with phalloidin bound and the other with jasplakinolide bound, representing closed and open D‐loop actin state, respectively (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}D). The two distinct fluorescent F‐actin populations were incubated together with varying concentrations of FAM‐lifeAct peptide and visualized in the same reaction chamber using TIRF microscopy ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}; Fig [3](#embj2019104006-fig-0003){ref-type="fig"}C). At micromolar concentrations, we began to observe F‐actin labeling by FAM‐lifeAct; however, the co‐localization was favored towards the phalloidin F‐actin form (Fig [3](#embj2019104006-fig-0003){ref-type="fig"}C and D). We quantified the fluorescence intensity ratio of FAM‐lifeAct for phalloidin versus jasplakinolide F‐actin ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}; Fig [3](#embj2019104006-fig-0003){ref-type="fig"}D) and found that a three to fourfold fluorescence increase toward the phalloidin‐bound F‐actin, i.e., closed D‐loop conformation. This trend and the fluorescent intensity ratio were observed at different concentrations of lifeAct (Figs [3](#embj2019104006-fig-0003){ref-type="fig"}C and D, and [EV3](#embj2019104006-fig-0003ev){ref-type="fig"}). The striking preference of phalloidin over jasplakinolide F‐actin thus strongly suggests that lifeAct preferentially binds to the closed state of D‐loop conformation of actin monomers in F‐actin.

![LifeAct recognizes the closed D‐loop state of F‐actin\
A, BOverlay of F‐actin:ADP‐bound LifeAct (actin in blue and magenta ribbon representation and lifeAct in red cartoon) and jasplakinolide (in gray).CRepresentative TIRF images of lifeAct‐binding experiments as indicated. The remaining lifeAct concentration images are shown in Fig EV3. Scale bar = 5 μm.DMean ratio of lifeAct fluorescent intensity bound to phalloidin and jasplakinolide F‐actin (mean and SEM; *n* = 2 or three independent experiments with \> 50 actin filament for each set).\
Source data are available online for this figure.](EMBJ-39-e104006-g006){#embj2019104006-fig-0003}

![TIRF images of lifeAct bound to F‐actin with phalloidin and jasplakinolide\
Representative TIRF images of lifeAct‐ versus phalloidin‐ and jasplakinolide‐bound F‐actin for concentrations as indicated. Scale bar = 5 μm.](EMBJ-39-e104006-g007){#embj2019104006-fig-0003ev}

The utrophin CH1 domain is sufficient for F‐actin interaction {#embj2019104006-sec-0006}
-------------------------------------------------------------

In our quest toward structural characterization of actin markers, we then focused on the utrophin actin‐binding domain, widely known as UTRN‐ABD or UTRN261, amino acids 1--261. The UTRN‐ABD contains two calponin homology domains (CH1 and CH2 domains), and previous structural and biochemical studies have proposed both the domains are necessary for actin interaction (Winder *et al*, [1995](#embj2019104006-bib-0046){ref-type="ref"}). The purified UTRN‐ABD was used to make a complex with F‐actin ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}), and the map was resolved to 3.6 Å resolution (Table [1](#embj2019104006-tbl-0001){ref-type="table"} and Fig [EV4](#embj2019104006-fig-0004ev){ref-type="fig"}). The UTRN‐ABD model was built from the available X‐ray structure coordinates (PDB ID: 1QAG) (Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}) and an additional amino‐terminal helix (amino acids 18--33), which was partially disordered in the X‐ray structure was built *de novo*. Although our cryoEM preparations contain complete UTRN‐ABD protein (amino acids 1--261), in the final reconstructed map we could model only less than 50% of the utrophin, amino acids 18--135, corresponding to the CH1 domain (Figs [4](#embj2019104006-fig-0004){ref-type="fig"}A and [EV4](#embj2019104006-fig-0004ev){ref-type="fig"}).

![Utrophin:F‐actin complex maps, structure validation, and quality control\
AOverlay of model with map, actin and utrophin CH1 are colored as green and red, respectively.BLocal resolution of utrophin CH1‐bound F‐actin map with color gradient chart as indicated.CFSC plots of the half‐maps (0.143) and the map versus model (0.5) for F‐actin:utrophin CH1 structure.DCloser view of ABD1 (amino‐terminal helix) utrophin map with key residues marked.](EMBJ-39-e104006-g009){#embj2019104006-fig-0004ev}

![Utrophin CH1 domain structure and F‐actin interaction sites\
ASurface representation of F‐actin--ADP, five monomers marked as *n* series from barbed to pointed end. The utrophin CH1 domain in orange interacts with two adjacent actin monomers thus following the actin helical pattern. The crystal structure of dystrophin/utrophin in gray (1DXX) superimposed with cryoEM utrophin CH1 model, boundary of CH1 is marked by an arrow.BCloser view of utrophin CH1 model, the yellow, orange, and red region depicts ABD1, ABD2, and ABD2′ sites, respectively. The ABD1 and ABD2 sites are restricted to *n* ^th^ actin monomer, and the ADB2\` site partially interacts with the neighboring *n* + 2^nd^ actin monomer.C--EResidual level information of key amino acids interacting with actin monomers from ABD2: N109 (C); ABD2\' site: V87 (D); and ABD1: I22, H29 (E).](EMBJ-39-e104006-g008){#embj2019104006-fig-0004}

Previous work subdivided the CH1 domain of UTRN‐ABD into ABD1 (amino acids 31--44) and ABD2 (amino acids 105--132) (Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}). From our F‐actin‐bound structure, we could redefine the boundaries of ABD sites; ABD1 (amino acids 18--33), ABD2 (amino acids 107--126) and a newly identified ABD site in between ABD1 and ABD2, named ABD2′ (amino acids 84--94; Fig [4](#embj2019104006-fig-0004){ref-type="fig"}B). ABD1 is the amino‐terminal helix, which mainly interacts with the SD1 of the *n* ^th^ actin monomer (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}A and B). Both ABD2 and ABD2′ interact with SD2, chiefly with the D‐loop region of the *n* ^th^ actin monomer, which remains in a closed conformation (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}A and B). Additionally, ABD2′ is the only site that interacts with the SD1 of adjacent *n* + 2^nd^ actin monomer (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}A and B). The binding site and architecture of UTRN‐ABD‐CH1 are similar to the recently reported FLNaABD (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}); however, in our UTRN‐ABD an additional amino‐terminal helix is visible, extending toward the barbed end of the actin monomer (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}A and B).

To validate our structural model of the UTRN‐ABD:actin complex and the newly defined ABD1 (amino‐terminal helix) and ABD2′ region, we performed mutagenesis of key interacting residues (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}C--E) and co‐sedimentation assays with F‐actin ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}; Appendix Fig S3). From the ABD1 helix, we chose residues that have their side chains facing toward actin; thus, I22 makes hydrophobic contacts with P27, V30, and Y337 of actin residues, and H29 engages in a cation‐pi interaction with R28 and R95 of actin (Figs [4](#embj2019104006-fig-0004){ref-type="fig"}E and [EV4](#embj2019104006-fig-0004ev){ref-type="fig"}D). At the core of the CH1 domain (ABD2), we included N109, which makes electrostatic interactions with actin K50 and H88 side chains and the main chain carbonyl group of S52 and V54 (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}C). Additionally, we included V87D from the newly identified ABD2′, which makes hydrophobic contacts with Y143 of the SD1 of the adjacent *n* + 2^nd^ actin monomer and M44 from the D‐loop of the *n* ^th^ monomer (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}D). In summary, we tested the following mutants, I22D and H29A from the ABD1 site, V87D and N109A for ABD2′ and ABD2 sites, respectively (Fig [4](#embj2019104006-fig-0004){ref-type="fig"}B--E).

Co‐sedimentation assays of mutants compared to the wild‐type UTRN‐ABD protein show more than 50 and 100 times decrease in binding constants for V87D and N109A mutants, respectively (Fig [5](#embj2019104006-fig-0005){ref-type="fig"}A and B and [Appendix Fig S3](#embj2019104006-sup-0001){ref-type="supplementary-material"}). The decrease in affinity by V87D and N109A mutants indicate that the core binding is mediated by the ABD2′ and ABD2 sites. Moreover, the reduced binding constants of the V87D mutant data indicates that the UTRN‐ABD interacts with two neighboring (*n* ^th^ and *n* + 2^nd^) actin monomers and thus has the ability to bind to F‐actin, but not actin monomers (Winder *et al*, [1995](#embj2019104006-bib-0046){ref-type="ref"}). Our mutation analysis also shows that the I22D, but not H29A has a profound impact in binding affinities, suggesting that the ABD1 (amino‐terminal helix) might also play an important role in actin binding (Fig [5](#embj2019104006-fig-0005){ref-type="fig"}B).

![Mutation analysis of utrophin:F‐actin‐binding interface\
ARepresentative Coomassie‐stained SDS‐PAGE gels of UTRN‐ABD and UTRN‐V87D co‐sedimentation with F‐actin. Pellet (top) and supernatant (bottom) fractions of individual co‐sedimentation reactions of increasing utrophin concentrations, and uncropped gel images of all the co‐sedimentation reactions are presented in Appendix Fig S3.BApparent *K* ~d~ indicated was calculated from the titration data of co‐sedimentation assays of utrophin wild‐type (1.8 μM) and mutants; H29A (2.8 μM), I22D (38 μM), V87D (\> 100 μM), and N109A (55 μM) as indicated. Data points for each concentration were averaged from three independent experiments; error bars represent SD between independent experiments.CConfocal images of U20S cells transfected with GFP tagged UTRN‐mini and mCherry‐UTRN‐ABD, stained with SIR‐Actin shows F‐actin structures, mainly stress fibers. Scale bar = 5 μm.DCo‐localization analysis by intensity plot of GFP UTRN‐mini, mCherry‐UTRN‐ABD, and SiR‐Actin fluorescence using line scan of the region as indicated by the yellow line in (C).\
Source data are available online for this figure.](EMBJ-39-e104006-g010){#embj2019104006-fig-0005}

Our mutagenesis study and structural model also suggests that ABD2′ and ABD2 sites of UTRN‐ABD could be sufficient for F‐actin interaction (Figs [4](#embj2019104006-fig-0004){ref-type="fig"}B and C, and [5](#embj2019104006-fig-0005){ref-type="fig"}B). Therefore, we generated a truncated version called UTRN‐mini encompassing amino acids 35--136, which was then tagged with GFP and compared with UTRN‐ABD mcherry in U20S cell ([Materials and Methods](#embj2019104006-sec-0008){ref-type="sec"}). Co‐localization analysis shows that the UTRN‐mini versus UTRN‐ABD labeling of actin is nearly identical (Fig [5](#embj2019104006-fig-0005){ref-type="fig"}C and D). Together, from our structure and cell labeling studies we conclude that the CH1 domain of utrophin encompassing ABD2 and ABD2′ is sufficient for F‐actin interaction.

Discussion {#embj2019104006-sec-0007}
==========

Using cryoEM, we have determined near atomic resolution structures of phalloidin, lifeAct, and utrophin bound to F‐actin structures (Table [1](#embj2019104006-tbl-0001){ref-type="table"}). These structures represent the first high‐resolution comparison of most widely used F‐actin cellular markers. Similar to most of the known F‐actin structural models (Ge *et al*, [2014](#embj2019104006-bib-0017){ref-type="ref"}; Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}; Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}; Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}; Chou & Pollard, [2019](#embj2019104006-bib-0010){ref-type="ref"}), the markers studied here do not induce any larger deviations in helical parameters of the actin filament (Table [1](#embj2019104006-tbl-0001){ref-type="table"}). By comparing the apo and phalloidin‐bound F‐actin--ADP structures, we conclusively show that phalloidin closely resembles the ADP state of actin (Fig [1](#embj2019104006-fig-0001){ref-type="fig"}D). This is in stark contrast to jasplakinolide, which shares the same binding site as phalloidin but causes the D‐loop of actin monomers to adopt an open conformation, mimicking the ADP‐Pi state (Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}). A recent structural study, which determined phalloidin‐bound F‐actin in different nucleotide states arrived at a similar conclusion (Pospich *et al*, [2020](#embj2019104006-bib-0038){ref-type="ref"}). Phalloidin is widely used in visualizing F‐actin in cells; however, phalloidin labeling is currently restricted to only fixed cells. Since phalloidin does not induce any conformational changes, an SiR‐actin equivalent of phalloidin fluorescent derivative will be valuable to the actin cytoskeleton community.

Previous studies with utrophin tandem CH1 and CH2 domains, including an X‐ray crystal structure (Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}), low‐resolution electron microscopy models (Moores & Kendrick‐Jones, [2000](#embj2019104006-bib-0031){ref-type="ref"}; Galkin *et al*, [2002](#embj2019104006-bib-0015){ref-type="ref"}, [2003](#embj2019104006-bib-0016){ref-type="ref"}), and truncation studies (Singh *et al*, [2017](#embj2019104006-bib-0042){ref-type="ref"}), portray an ambiguous picture of utrophin:F‐actin interaction and the actin‐binding sites. In our cryoEM reconstructions, we observe densities corresponding to the CH1 domain (amino acids 18--135) and an additional amino‐terminal helix (amino acids 18--30), which was disordered in an earlier crystal structure (Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}) (Figs [4](#embj2019104006-fig-0004){ref-type="fig"}A and [EV4](#embj2019104006-fig-0004ev){ref-type="fig"}D). The utrophin CH1 domain architecture and the actin interaction regions are similar to the recently reported mutant FLNaCH1 (filamin) cryoEM structure (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}). However, unlike the FLNaABD, where the CH2 domain showed weaker interaction and poor density map (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}), we could not visualize utrophin CH2 domain in our reconstructions indicating flexibility. Our structural observations of the CH1 domain are consistent with the biophysical characterization of UTRN‐ABD, where upon actin binding of the CH1 and CH2 domain gets separated and adopts an open conformation (Lin *et al*, [2011](#embj2019104006-bib-0026){ref-type="ref"}; Broderick *et al*, [2012](#embj2019104006-bib-0006){ref-type="ref"}), which is in contrast to the filamin tandem CH domains. The utrophin‐F‐actin structure also describes the important actin‐binding sites, for example, the ABD2′ and ABD1, a helix unique to utrophin CH1 domain. Truncation studies guided by our structural model suggests that amino acids 35--136, i.e., the CH1 domain encompassing ABD2′ and ABD2 sites (UTRN‐mini), could be sufficient for F‐actin interaction ([Appendix Fig S4](#embj2019104006-sup-0001){ref-type="supplementary-material"}). The UTRN‐mini is a 101 amino acid protein that labels F‐actin structures in cells (Fig [5](#embj2019104006-fig-0005){ref-type="fig"}C and D), which will occupy lesser footprint on F‐actin compared to UTRN‐ABD and could be advantageous in actin labeling experiments. The UTRN‐mini is in line with biochemical studies of utrophin CH1 domain (Singh *et al*, [2014](#embj2019104006-bib-0041){ref-type="ref"}) and filamin truncation studies, where FLNaCH1 shows similar actin labeling as FLNaABD (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}). Utrophin is also commonly used in biophysical experiments as a load in myosin motility assays (Aksel *et al*, [2015](#embj2019104006-bib-0003){ref-type="ref"}), and the mutations described here will be valuable to biophysicists in fine tuning the load exerted by utrophin in the motor assays. Together, we conclude that the CH1 domain of utrophin is an important element for F‐actin interaction and can be used to label F‐actin structures in cells (Fig [5](#embj2019104006-fig-0005){ref-type="fig"}C and D).

The lifeAct:F‐actin complex cryoEM structure reveals that the lifeAct peptide adopts a 3‐turn alpha‐helix, as suggested by secondary structure prediction algorithms. The lifeAct interaction with actin is predominantly through hydrophobic contacts, encompassing two neighboring actin monomers. A key feature of this interaction is the overlapping site with D‐loop (Figs [2](#embj2019104006-fig-0002){ref-type="fig"} and [3](#embj2019104006-fig-0003){ref-type="fig"}), from which we hypothesized that lifeAct could sense the closed D‐loop conformation, a hallmark of the F‐actin--ADP and ADP‐Pi state. Our *in vitro* reconstitution experiments using phalloidin and jasplakinolide recapitulates the structural hypothesis that lifeAct detects F‐actin in its closed D‐loop state. Although our structural and biochemical studies support the importance of the D‐loop in F‐actin binding, lifeAct can interact with G‐actin even more tightly (Riedl *et al*, [2008](#embj2019104006-bib-0039){ref-type="ref"}), which is devoid of the D‐loop from the adjacent actin monomer. Thus, a different binding state must exist for G‐actin. We predict that in the absence of the D‐loop, the charged carboxy‐terminus of lifeAct might play a dominant role in mediating additional electrostatic interactions with G‐actin. However, in the case of the open D‐loop state, the disruption of the hydrophobic pocket could be sufficient to prevent lifeAct\'s interaction with the F‐actin.

Previous cell biology experiments have indicated two limitations of lifeAct: (i) affecting actin polymerization dynamics (Spracklen *et al*, [2014](#embj2019104006-bib-0043){ref-type="ref"}; Courtemanche *et al*, [2016](#embj2019104006-bib-0011){ref-type="ref"}) and (ii) inability to label certain actin structures (Munsie *et al*, [2009](#embj2019104006-bib-0032){ref-type="ref"}; Belin *et al*, [2014](#embj2019104006-bib-0005){ref-type="ref"}). The structural model provided here should help guide the creation of new lifeAct variants that will mitigate G‐actin binding, further improving the suitability of the lifeAct probe. For the second limitation, the most common explanation is that lifeAct might be overlapping with other actin‐binding proteins (Fig [6](#embj2019104006-fig-0006){ref-type="fig"}). Based on the experiments described here for lifeAct, we also suggest that the actin structures devoid of lifeAct signal might also reflect different biochemical or alternate D‐loop conformations states of actin in cells.

![Interface comparison of UTRN, LifeAct with myosin, and tropomyosin\
Surface representation of F‐actin with five monomers as marked. Footprint (in red) of actin monomers and respective residues interacting with lifeAct, utrophin CH1, myosin, and tropomyosin as indicated and the D‐loop is shown circled. The myosin and tropomyosin footprints were derived from PDB IDs 6C1D and 5JLF, respectively.](EMBJ-39-e104006-g011){#embj2019104006-fig-0006}

With the recent advances in cryoEM, several actin‐binding proteins complexed with F‐actin have been characterized (Behrmann *et al*, [2012](#embj2019104006-bib-0004){ref-type="ref"}; Ge *et al*, [2014](#embj2019104006-bib-0017){ref-type="ref"}; Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}; Mentes *et al*, [2018](#embj2019104006-bib-0029){ref-type="ref"}). A common theme emerging from these structures is that SD1 and SD2 encompassing the D‐loop region of actin is a preferred site for actin‐binding proteins (Fig [6](#embj2019104006-fig-0006){ref-type="fig"}). Our lifeAct‐ and utrophin‐bound F‐actin structures also show that they overlap with myosin‐, cofilin‐, and coronin‐binding sites (Ge *et al*, [2014](#embj2019104006-bib-0017){ref-type="ref"}; Tanaka *et al*, [2018](#embj2019104006-bib-0044){ref-type="ref"}), but not with that of tropomyosin (Fig [6](#embj2019104006-fig-0006){ref-type="fig"}). Since the D‐loop is the sole element that undergoes conformational changes in actin, several reports have proposed that actin‐binding proteins might sense the D‐loop state. So far coronin and cofilin are known to sense the D‐loop in open and closed conformation, respectively (Cai *et al*, [2007](#embj2019104006-bib-0009){ref-type="ref"}; Merino *et al*, [2018](#embj2019104006-bib-0030){ref-type="ref"}). However, upon sensing the closed D‐loop conformation, cofilin distorts the F‐actin structure resulting in severing of the actin filament (Tanaka *et al*, [2018](#embj2019104006-bib-0044){ref-type="ref"}). Our work here describes the D‐loop conformation sensing by lifeAct, which presents lifeAct as the first *bona fide* sensor for the closed D‐loop of actin.

In summary, our structural work combined with previous cell biological investigations of various actin markers offers insights into the nature of actin cell markers and their interactions with F‐actin, providing an invaluable resource to the actin cytoskeleton community in choosing appropriate actin markers in their investigations.

Materials and Methods {#embj2019104006-sec-0008}
=====================

DNA constructs and reagents {#embj2019104006-sec-0009}
---------------------------

Human UTRN‐ABD (amino acids 1--261) was cloned in pET28a vector with amino‐terminal His tag, using GFP‐UtrCH (addgene plasmid \#26737) as a template. UTRN‐ABD mutations were generated in the same vector by Quickchange site‐directed mutagenesis (Strategene). mcherry‐UTRN‐ABD and eGFP‐UTRN‐mini (amino acids 35--136) were cloned in mcherry and eGFP pCMV vector, respectively. pLenti‐LifeAct‐EGFP BlastR was a gift from Ghassan Mouneimne (Addgene plasmid \#84383). LifeAct mutations were created in the pLenti‐LifeAct‐EGFP BlastR using methodology as mentioned for UTRN. Alexafluor‐568‐phalloidin (Thermo Fisher Scientific Cat. No. A12380) and SiR‐actin (Spirochrome Cat. No. Cy‐SC001) were purchased. FAM‐LifeAct peptides were custom synthesized from LifeTein, USA.

Protein purification {#embj2019104006-sec-0010}
--------------------

6xHis‐tagged UTRN‐ABD and mutants were expressed in *Escherichia coli* Rosetta DE3 strain and induced with 0.25 mM IPTG overnight at 20°C. Bacterial cells were pelleted and resuspended in lysis buffer (50 mM Tris--Cl pH‐7.5, 150 mM NaCl, 20 mM Imidazole, 0.1% Tween‐20, and Protease inhibitor cocktail tablet (Roche, Cat. No. 04693159001)). The cells were lysed using sonication, and the lysate was clarified at 39,190 *g* for 30 min. The supernatant fraction containing proteins were loaded on 5 ml His‐Trap column (GE Healthcare) and eluted with a linear gradient of elution buffer containing 40--500 mM Imidazole, 500 mM NaCl, and 5 mM beta‐mercaptoethanol. The utrophin protein fractions were pooled, concentrated, and loaded on to the Superdex‐200 16/600 column, pre‐equilibrated with 50 mM Tris--HCl pH‐7.5, 150 mM NaCl, 2 mM TCEP, and 0.1% Tween‐20. Pure fractions were concentrated using 3 kDa MWCO centrifugal filter unit (Millipore), flash‐frozen in liquid nitrogen, and stored at −80°C until use.

Actin co‐sedimentation assays {#embj2019104006-sec-0011}
-----------------------------

Actin, purified from chicken breast (*Gallus gallus*) into G buffer (2 mM Tris pH 8, 0.2 mM ATP, 2 mM DTT, 0.2 mM CaCl~2~) using Spudich laboratory protocol (Pardee & Spudich, [1982](#embj2019104006-bib-0033){ref-type="ref"}). G‐actin was polymerized in F‐actin buffer (25 mM Tris--Cl, 200 mM KCl, 2 mM MgCl~2~, and 1 mM ATP) for 2 h at room temperature. Polymerized actin (7.5 μM) was titrated with increasing amounts of UTRN‐ABD and mutants in co‐sedimentation assay buffer (10 mM Tris--Cl pH 8, 0.5 mM ATP, 0.2 mM DTT, 2 mM MgCl~2~, and 50 mM KCl). The mixture was incubated at room temperature for 20 min and centrifuged at 100,000 *g* for 30 min in a Beckman TLA‐100 rotor. Supernatants were collected, and protein pellets were suspended in equal volume of co‐sedimentation assay buffer. The supernatant, pellet, and input samples were loaded in a 10% SDS--PAGE gel for separation. Gels were stained with Coomassie blue and scanned using the iBright FL1000 (Invitrogen). Fiji ImageJ was used for densitometric analysis. For Lifeact‐binding assay, polymerized actin (5 μM) was titrated with increasing amount of FAM‐lifeAct‐17 or FAM‐lifeAct‐14 in KMEI buffer (50 mM KCl, 1 mM MgCl~2~, 1 mM EGTA, 10 mM Imidazole pH 7.5). The mixture was incubated at room temperature for 30 min and centrifuged at 350,000 *g* for 30 min in Beckman TLA‐100 rotor. Pellet fractions were suspended in equal volume of KMEI buffer, and the bound lifeAct was measured using fluorescence at 485/520 nm using Varioskan Lux multimode microplate (Thermo Fisher Scientific). Data points were fitted to a one‐site binding model using Prism software (GraphPad) to calculate the apparent binding affinity and stoichiometry as described earlier (Riedl *et al*, [2008](#embj2019104006-bib-0039){ref-type="ref"}; Singh *et al*, [2014](#embj2019104006-bib-0041){ref-type="ref"}).

Sample and grid preparation for cryoEM {#embj2019104006-sec-0012}
--------------------------------------

Freshly prepared G‐actin was used for polymerization. For F‐actin‐phalloidin complex, actin was polymerized in F‐actin buffer (10 mM Imidazole pH 7.4, 200 mM KCl, 2 mM MgCl~2~, 1 mM ATP) at room temperature for 2 h and then Alexafluor‐568‐phalloidin (1/2 ratio) was mixed and incubated overnight at 4°C. For F‐actin‐utrophin, F‐actin‐ADP‐Apo and F‐actin‐lifeAct complex, polymerization was induced with KMEI buffer (50 mM KCl, 1 mM MgCl~2~, 0.5 mM ATP, 1 mM EGTA, and 10 mM Imidazole pH 7.5) at 4°C overnight.

In the case of F‐actin--phalloidin and F‐actin‐ADP‐Apo, we applied 3.0--3.5 μl of sample onto a freshly glow‐discharged Quantifoil Au 1.2/1.3, 300 mesh grids. For F‐actin--utrophin, 5--8 μM of F‐actin was applied on to Au 1.2/1.3 grid and then 4--5 molar excess of utrophin was mixed to it and incubated for 30--60 s at \> 95% humidity, then blotted for 3--3.5 s. For F‐actin--lifeAct, Au 0.6/1.0 grid was used and same amount of F‐actin as above with excess molar concentration of lifeAct peptide was used for sample preparation. Grids were prepared with Thermo Fisher Scientific Vitrobot Mark IV. All grids were incubated for 30--60 s at \> 95% humidity, then blotted for 3--3.5 s. Immediately after blotting, the grids were plunge‐frozen in liquid ethane.

CryoEM data collection {#embj2019104006-sec-0013}
----------------------

The datasets were collected on FEI Titan Krios G3 transmission electron microscope equipped with a FEG at 300 kV with the automated data collection software EPU (Thermo Fisher Scientific) at the National CryoEM facility, Bangalore. Images of the F‐actin--phalloidin, F‐actin‐UTRN‐ABD and F‐actin‐LifeAct were collected with a Falcon III detector operating in linear mode at a nominal magnification of 59,000× and a calibrated pixel size of 1.38 Å, while the F‐actin--ADP (apo) was collected at a nominal magnification of 75,000× and a pixel size of 1.08 Å. In all cases, we acquired one image per grid hole. Table [1](#embj2019104006-tbl-0001){ref-type="table"} contains the details on exposure time, frame number, and electron dose for all the datasets.

Data processing and model building {#embj2019104006-sec-0014}
----------------------------------

Unaligned frame images were manually inspected and evaluated for ice and filament quality. After manual removal of bad images, the remaining movie micrographs were motion corrected with either by Unblur (Grant & Grigorieff, [2015](#embj2019104006-bib-0018){ref-type="ref"}) or by algorithm inbuilt in Relion 3.0 (Scheres, [2012](#embj2019104006-bib-0040){ref-type="ref"}; He & Scheres, [2017](#embj2019104006-bib-0020){ref-type="ref"}). CTF estimation was performed with GCTF (Zhang, [2016](#embj2019104006-bib-0504){ref-type="ref"}) on the full‐dose weighted motion‐corrected sums. For all the datasets, filaments were manually selected and processed with Relion 3.0 (He & Scheres, [2017](#embj2019104006-bib-0020){ref-type="ref"}). We used a box size of 256 pixels for phalloidin‐, utrophin‐ and lifeAct‐bound F‐actin dataset and 320 pixels for the F‐actin--ADP (apo) with the interbox distance of 27.5 Å for extraction of segments. Subsequently, 2D classification in Relion 3.0 was used to remove bad segments. To further remove the partially decorated filament, we did helical 3D classification using F‐actin (EMDB‐1990) as a reference, which was low‐pass filtered to 30--35 Å, to avoid reference bias. The best decorated 3D classes were combined and used for refinement using same reference as above starting with the sampling rate of 1.8°. All refinement steps were performed with soft mask containing 75--80% of the filament. To further improve the maps, we performed CTF refinement and Bayesian polishing of lifeAct‐ and utrophin‐bound F‐actin datasets (Zivanov *et al*, [2018](#embj2019104006-bib-0048){ref-type="ref"}). The polished particles were subsequently refined, and the resolutions for all datasets were estimated with mask and post‐processing option in Relion 3.0. Local resolution of the maps were estimated with Resmap (Kucukelbir *et al*, [2014](#embj2019104006-bib-0503){ref-type="ref"}).

We used F‐actin structure (PDB‐6BNO) as a starting atomic model in Chimera (Pettersen *et al*, [2004](#embj2019104006-bib-0034){ref-type="ref"}) to fit the F‐actin model in the map for all datasets. Phalloidin coordinates were used from PDB‐6D8C (Iwamoto *et al*, [2018](#embj2019104006-bib-0021){ref-type="ref"}). For F‐actin‐utrophin complex, utrophin CH1 domain from crystal structure PBD‐1QAG was used as the starting model (Keep *et al*, [1999](#embj2019104006-bib-0022){ref-type="ref"}). Coot (Emsley *et al*, [2010](#embj2019104006-bib-0014){ref-type="ref"}) was used for model building for all datasets and real space refined using Phenix (Adams *et al*, [2010](#embj2019104006-bib-0001){ref-type="ref"}; Afonine *et al*, [2018](#embj2019104006-bib-0002){ref-type="ref"}). All structural models were validated in MolProbity (Williams *et al*, [2018](#embj2019104006-bib-0045){ref-type="ref"}) and PDBe site. Figures were generated using Pymol (DeLano, [2018](#embj2019104006-bib-0002){ref-type="ref"}), Chimera (Goddard *et al*, [2007](#embj2019104006-bib-0502){ref-type="ref"}), and Coot (Emsley *et al*, 2010) software programs.

Cell imaging {#embj2019104006-sec-0015}
------------

Wild‐type U2OS cells were obtained as a gift from Prof. Satyajit Mayor\'s laboratory, NCBS, Bangalore, India. For all the experiments, U2OS cells were cultured in McCoy\'s 5A (Sigma Aldrich, M4892) media supplemented with 2.2 g/l sodium bicarbonate, 10% fetal bovine serum (FBS) and 1× PenStrep (cat. no. 15‐140‐122 Gibco Fisher Scientific) in a humidified 37°C incubator with 5% carbon dioxide. Around 20,000 to 30,000 cells were seeded in ibidi glass‐bottom dishes (Cat. No. 81218, Ibidi), and transfection was carried out at 60--70% confluency of the cells with total of 1 μg of plasmid DNA used for transfection. All the transfection experiments were carried out with jet prime transfection reagent (cat. no. 114‐15 polypus transfection) as described in manufacturer\'s protocol. Five hundred nanogram of UTRN‐mini construct (UTRN 35‐136) tagged with N‐terminus EGFP were co‐transfected with 500 ng plasmid of mcherry tagged UTRN‐ABD in the 10% serum containing media. The transfection media was changed with fresh media after 4--6 h of transfection. Cells were imaged after 24 h of transfection with SiR‐actin (Cat. no. CY‐SC001 Spirochrome kit; Cytoskeleton, Inc) staining in the complete media. All the images were obtained at 60× oil objective (1.42NA) with 2,048\*2,048 frame size and 0.5--1 μm optical sections on FV3000 Olympus confocal microscope equipped with 488, 561, and 640 laser for GFP, cy3, and cy5 channels, respectively. All the images obtained through Olympus software and were analyzed on Fiji ImageJ.

*In vitro* actin labeling assay and TIRF microscopy {#embj2019104006-sec-0016}
---------------------------------------------------

Flow chambers of \~ 10 μl volume were prepared using double‐sticky tape, coverslips, and cover glass. The flow chamber was incubated with Protein G (Sigma, Cat. No. 08062) for 10 min followed by anti‐his antibody (Sigma, Cat. No. 11922416001) for another 10 min. After washing with KMEI buffer without ATP, UTRN‐ABD‐6xHis was flowed to attach actin filament with the coverslip. The Phalloidin‐Actin‐568 and SiR‐actin 640 F‐actin were prepared separately and added together with different concentration of FAM‐lifeAct. The mixture was incubated in tube for 5--10 min and flowed in the chamber for visualization. Flow chambers were imaged at 100× oil objective 1.49NA under the total internal reflection mode using Nikon Ti2 H‐TIRF system with 488, 561, and 640 laser lines. The images were acquired for all the three channels near glass surface sequentially with appropriate spectrum filter sets using s‐CMOS camera (Hamamatsu Orca Flash 4.0) controlled by NIS‐elements software. All images and data were analyzed using Fiji ImageJ software.
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